KS Biomedix licenses TransMID brain cancer product to Nycomed in European collaboration.
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D003299:Cooperative Behavior; D004345:Drug Industry / Q000191:economics*; D005060:Europe; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008004:Licensure / Q000191:economics*
D000970:Antineoplastic Agents